Haemophilus influenzae
Haemophilus influenzae type b
Haemophilus Vaccines
Meningitis, Haemophilus
Vaccines, Conjugate
Bacterial Capsules
Haemophilus
Diphtheria-Tetanus-Pertussis Vaccine
Diphtheria Toxoid
Immunization Schedule
Poliovirus Vaccine, Inactivated
Bacterial Outer Membrane Proteins
Counterimmunoelectrophoresis
Diphtheria-Tetanus-acellular Pertussis Vaccines
Ampicillin
Meningitis
Vaccination
Bacterial Vaccines
Meningitis, Bacterial
Hepatitis B Vaccines
Streptococcus pneumoniae
Immunization, Secondary
Nasopharynx
Haemophilus ducreyi
Oropharynx
Neisseria meningitidis
Latex Fixation Tests
Blood Bactericidal Activity
Carrier State
Transferrin-Binding Proteins
Epiglottis
Pharynx
Fimbriae, Bacterial
Meningitis, Pneumococcal
Immunoglobulin G
Meningitis, Meningococcal
Antibody Affinity
Meningococcal Vaccines
Immunization Programs
Cerebrospinal Fluid
Neisseria meningitidis, Serogroup C
Sepsis
Microbial Sensitivity Tests
Cross Reactions
Tetanus
Pertussis Vaccine
Immunization
Chinchilla
Moraxella (Branhamella) catarrhalis
Pneumococcal Vaccines
Chloramphenicol
Ampicillin Resistance
Serotyping
Agglutination Tests
Lipopolysaccharides
Molecular Sequence Data
Panophthalmitis
Transformation, Bacterial
Antibody Formation
Diphtheria
Clostridium tetani
Bacterial Adhesion
Vaccines
Enzyme-Linked Immunosorbent Assay
Porins
Incidence
Diphtheria Toxin
Haemophilus parasuis
Amino Acid Sequence
Immunoglobulin Isotypes
Immunoglobulin Allotypes
Gambia
Haemophilus parainfluenzae
Population Surveillance
Cephalosporins
Dose-Response Relationship, Immunologic
Base Sequence
beta-Lactamases
Drug and Narcotic Control
Ceftriaxone
Poliovirus Vaccines
Immunization, Passive
Immunoglobulin A
Hemagglutination
Indians, North American
Rabbits
Opsonin Proteins
Mumps Vaccine
Culture Media
Immunity, Maternally-Acquired
Cloning, Molecular
Virulence
Immune Sera
Age Factors
Bacteremia
Immunoglobulin M
Purpura
Vaccines, Acellular
Complement System Proteins
Fimbriae Proteins
Immunosorbent Techniques
Escherichia coli
Respiratory Tract Infections
Species Specificity
Amoxicillin-Potassium Clavulanate Combination
Mouth Mucosa
Chancroid
Antibody Specificity
Mutation
Whooping Cough
Serum Bactericidal Test
Carrier Proteins
Rubella Vaccine
Electrophoresis, Gel, Pulsed-Field
Drug Resistance, Microbial
Blotting, Southern
Haemophilus somnus
Rifampin
Oligosaccharides
Ear, Middle
Radioimmunoassay
Developing Countries
Prospective Studies
Antigens, Surface
Blood
Phagocytosis
Immunoglobulin Variable Region
Cefuroxime
Treatment Failure
Rats, Inbred Strains
Bacterial Typing Techniques
Otitis Media with Effusion
Restriction Mapping
Immunoglobulin kappa-Chains
Bacteria
Drug Incompatibility
Electrophoresis, Polyacrylamide Gel
Transformation, Genetic
Neisseria meningitidis, Serogroup A
Chloramphenicol Resistance
Adhesins, Bacterial
Azithromycin
Membrane Proteins
Ketolides
Erythromycin
A case-control study of risk factors for Haemophilus influenzae type B disease in Navajo children. (1/240)
To understand the potential risk factors and protective factors for invasive Haemophilus influenzae type b (Hib) disease, we conducted a case-control study among Navajo children less than two years of age resident on the Navajo Nation. We analyzed household interview data for 60 cases that occurred between August 1988 and February 1991, and for 116 controls matched by age, gender, and geographic location. The Hib vaccine recipients were excluded from the analyses. Conditional logistic regression models were fit to examine many variables relating to social and environmental conditions. Risk factors determined to be important were never breast fed (odds ratio [OR] = 3.55, 95% confidence interval [CI] = 1.52, 8.26), shared care with more than one child less than two years of age (OR = 2.32, 95% CI = 0.91, 5.96); wood heating (OR = 2.14, 95% CI = 0.91, 5.05); rodents in the home (OR = 8.18, 95% CI = 0.83, 80.7); and any livestock near the home (OR = 2.18, 95% CI = 0.94, 5.04). (+info)Efficacy of Haemophilus influenzae type b conjugate vaccines and persistence of disease in disadvantaged populations. The Haemophilus Influenzae Study Group. (2/240)
OBJECTIVES: The purpose of this study was to evaluate the effectiveness of Haemophilus influenzae type b (Hib) conjugate vaccines among children aged 2 to 18 months and to determine risk factors for invasive Hib disease during a period of declining incidence (1991-1994). METHODS: A prospective population-based case-control study was conducted in a multistate US population of 15.5 million. A laboratory-based active surveillance system was used for case detection. RESULTS: In a multivariate analysis, having a single-parent mother (odds ratio [OR] = 4.3, 95% confidence interval [CI] = 1.2, 14.8) and household crowding (OR = 3.5, 95% CI = 1.03, 11.7) were risk factors for Hib disease independent of vaccination status. After adjustment for these risk factors, the protective efficacy of 2 or more Hib vaccine doses was 86% (95% CI = 16%, 98%). Among undervaccinated subjects, living with a smoker (P = .02) and several indicators of lower socioeconomic status were risk factors for Hib disease. CONCLUSIONS: Hib disease still occurs at low levels in the United States, predominantly in socioeconomically disadvantaged populations. Low immunization coverage may facilitate continuing transmission of Hib. Special efforts to achieve complete and timely immunization in disadvantaged populations are needed. (+info)Structural requirements of the major protective antibody to Haemophilus influenzae type b. (3/240)
Protective antibodies to the important childhood pathogen Haemophilus influenzae type b (Hib) are directed against the capsular polysaccharide (HibCP). Most of the antibody is encoded by a well-defined set of ("canonical") immunoglobulin genes, including the Vkappa A2 gene, and expresses an idiotypic marker (HibId-1). In comparison to noncanonical antibodies, the canonical antibody is generally of higher avidity, shows higher levels of in vitro bactericidal activity, and is more protective in infant rats. Using site-directed mutagenesis, we here characterize canonical HibCP antibodies expressed as antigen-binding fragments (Fabs) in Escherichia coli, define amino acids involved in antigen binding and idiotype expression, and propose a three-dimensional structure for the variable domains. We found that canonical Fabs, unlike a noncanonical Fab, bound effectively to HibCP in the absence of somatic mutations. Nevertheless, pronounced mutation-based affinity maturation was demonstrated in vivo. An almost perfect correlation was found between unmutated gene segments that mediated binding in vitro and those encoding canonical HibCP antibodies in vivo. Thus, the Vkappa A2a gene could be replaced by the A2c gene but not by the highly homologous sister gene, A18b, corresponding to the demonstrated usage of A2c but not of A18b in vivo. Similarly, only Jkappa1 and Jkappa3, which predominate in the response in vivo, were able to facilitate binding in vitro. These findings suggest that the restricted immunoglobulin gene usage in HibCP antibodies reflects strict structural demands ensuring relatively high affinity prior to somatic mutations-requirements met by only a limited spectrum of immunoglobulin gene combinations. (+info)Neutralization of macrophage inflammatory protein 2 (MIP-2) and MIP-1alpha attenuates neutrophil recruitment in the central nervous system during experimental bacterial meningitis. (4/240)
Chemokines are low-molecular-weight chemotactic cytokines that have been shown to play a central role in the perivascular transmigration and accumulation of specific subsets of leukocytes at sites of tissue damage. Using in situ hybridization (ISH), we investigated the mRNA induction of macrophage inflammatory protein 2 (MIP-2), MIP-1alpha, monocyte chemoattractant protein 1 (MCP-1), and RANTES. Challenge of infant rats' brains with Haemophilus influenzae type b intraperitoneally resulted in the time-dependent expression of MIP-2, MIP-1alpha, MCP-1, and RANTES, which was maximal 24 to 48 h postinoculation. Immunohistochemistry showed significant increases in neutrophils and macrophages infiltrating the meninges, the ventricular system, and the periventricular area. The kinetics of MIP-2, MIP-1alpha, MCP-1, and RANTES mRNA expression paralleled those of the recruitment of inflammatory cells and disease severity. Administration of anti-MIP-2 or anti-MIP-1alpha antibodies (Abs) resulted in significant reduction of neutrophils. Administration of anti-MCP-1 Abs significantly decreased macrophage infiltration. Combined studies of ISH and immunohistochemistry showed that MIP-2- and MIP-1alpha-positive cells were neutrophils and macrophages. MCP-1-positive cells were neutrophils, macrophages, and astrocytes. Expression of RANTES was localized predominantly to resident astrocytes and microglia. The present study indicates that blocking of MIP-2 or MIP-1alpha bioactivity in vivo results in decreased neutrophil influx. These data are also the first demonstration that the C-C chemokine MIP-1alpha is involved in neutrophil recruitment in vivo. (+info)Antibody response to accelerated Hib immunisation in preterm infants receiving dexamethasone for chronic lung disease. (5/240)
AIM: To study the effect of dexamethasone on the routine immunisation of preterm infants with chronic lung disease. METHODS: Serum samples were obtained before and after immunisation from an unselected cohort of 59 preterm infants. Haemophilus influenzae antibodies were measured using an ELISA method and differences in the geometric mean values between the two groups of babies analysed. RESULTS: Sixteen infants received no dexamethasone. Before and after immunisation antibody titres for those receiving no dexamethasone were 0.16 and 4.63 mcg IgG/ml. Corresponding values for those receiving dexamethasone were 0.10 and 0.51 mcg IgG/ml, respectively. CONCLUSION: Dexamethasone used in the treatment of chronic lung disease seems to significantly affect the antibody response of preterm infants to immunisation against Haemophilus influenzae. (+info)Effect of multiple mutations in the hemoglobin- and hemoglobin-haptoglobin-binding proteins, HgpA, HgpB, and HgpC, of Haemophilus influenzae type b. (6/240)
Haemophilus influenzae requires heme for growth and can utilize hemoglobin and hemoglobin-haptoglobin as heme sources. We previously identified two hemoglobin- and hemoglobin-haptoglobin-binding proteins, HgpA and HgpB, in H. influenzae HI689. Insertional mutation of hgpA and hgpB, either singly or together, did not abrogate the ability to utilize or bind either hemoglobin or the hemoglobin-haptoglobin complex. A hemoglobin affinity purification method was used to isolate a protein of approximately 120 kDa from the hgpA hgpB double mutant. We have cloned and sequenced the gene encoding this third hemoglobin/hemoglobin-haptoglobin binding protein and designate it hgpC. Insertional mutation of hgpC did not affect the ability of the strain to utilize either hemoglobin or hemoglobin-haptoglobin. An hgpA hgpB hgpC triple mutant constructed by insertional mutagenesis showed a reduced ability to use the hemoglobin-haptoglobin complex but was unaltered in the ability to use hemoglobin. A second class of mutants was constructed in which the entire structural gene of each of the three proteins was deleted. The hgpA hgpB hgpC complete-deletion triple mutant was unable to utilize the hemoglobin-haptoglobin complex and showed a reduced ability to use hemoglobin. We have identified three hemoglobin/hemoglobin-haptoglobin-binding proteins in Haemophilus influenzae. Any one of the three proteins is sufficient to support growth with hemoglobin-haptoglobin as the heme source, and expression of at least one of the three is essential for hemoglobin-haptoglobin utilization. Although the three proteins play a role in hemoglobin utilization, an additional hemoglobin acquisition mechanism(s) exists. (+info)The induction of immunologic memory after vaccination with Haemophilus influenzae type b conjugate and acellular pertussis-containing diphtheria, tetanus, and pertussis vaccine combination. (7/240)
The significance of reduced antibody responses to the Haemophilus influenzae type b (Hib) component of acellular pertussis-containing combination vaccines (DTaP-Hib) is unclear. A DTaP-Hib vaccine evaluated in infants vaccinated at ages 2, 3, and 4 months showed reduced anti-Hib polysaccharide IgG (geometric mean concentration [GMC], 1.23 microgram/mL; 57%, >1.0 microgram/mL). Polyribitolribosyl phosphate (PRP) and Hib conjugate (PRP-T) vaccine given as a booster during the second year of life was evaluated for the presence of immunological memory. After boosting, most children achieved anti-PRP IgG >1.0 microgram/mL, although the GMC was higher with PRP-T (88.5 microgram/mL) than with PRP vaccine (7.86 microgram/mL, P<.001). The GMC of the PRP group was higher than anticipated for naive PRP recipients of the same age. PRP-specific IgG avidity was significantly higher after boosting than after priming, providing further evidence for the generation of memory. Despite reduced immunogenicity, DTaP-Hib combination vaccines appear to prime for immunologic memory. (+info)The pathogenic role of fimbriae of Haemophilus influenzae type b in murine bacteraemia and meningitis. (8/240)
Complement activation and development of murine bacteraemia and meningitis following intranasal instillation of cell-bound fimbriated or non-fimbriated organisms were compared to clarify the role of fimbriae in the pathogenesis of illnesses caused by Haemophilus influenza type b (Hib). In-vitro resistance of non-fimbriate bacteria to the bactericidal effects of normal human serum was at least 400 times greater than that of fimbriate bacteria. The amount of C3 bound to fimbriate Hib was more than that to non-fimbriate Hib. When mice were infected with fimbriate bacteria, 11.5% died. When mice were infected with non-fimbriate bacteria, the mean number of viable organisms gradually increased or was constant up to day 7; 38.5% of these mice died. These in-vivo results were coincident with the in-vitro data. However, the content of polyribosyl ribitol phosphate (PRP) in fimbriate organisms was the same as in non-fimbriate organisms. These results indicate that fimbriate Hib may be less likely to produce bacteraemia and meningitis, correlating with the greater susceptibility to complement-mediated bacteriolysis and the lower mortality seen with this type of organism, although fimbriae increase adherence to epithelial cells (mucosal surface). (+info)Epidemiology of Haemophilus Infections:
* Incidence: Hib disease was once a major cause of childhood meningitis and sepsis, but the introduction of Hib vaccines in the 1980s has significantly reduced the incidence of invasive Hib disease. Non-invasive Hib disease, such as otitis media, is still common.
* Prevalence: Hib is the leading cause of bacterial meningitis in children under the age of 5 worldwide. In developed countries, the prevalence of invasive Hib disease has decreased significantly since the introduction of vaccines, but it remains a significant public health problem in developing countries.
* Risk factors: young age, poverty, lack of access to healthcare, and poor sanitation and hygiene are risk factors for Hib disease. Children under the age of 5, especially those under the age of 2, are at highest risk for invasive Hib disease.
Pathophysiology of Haemophilus Infections:
* Mechanisms of infection: H. influenzae can cause both respiratory and non-respiratory infections by colonizing the nasopharynx and other mucosal surfaces. The bacteria can then disseminate to other parts of the body, causing invasive disease.
* Immune response: the immune response to Hib infection involves both humoral and cell-mediated immunity. Antibodies play a crucial role in protecting against reinfection, while T cells and macrophages help to clear the bacteria from the body.
Clinical Presentation of Haemophilus Infections:
* Respiratory infections: H. influenzae can cause various respiratory tract infections, including bronchitis, pneumonia, and sinusitis. Symptoms may include fever, cough, sore throat, and difficulty breathing.
* Non-respiratory infections: Hib can cause a range of non-respiratory infections, including meningitis, epiglottitis, and septic arthritis. These infections can have more severe symptoms and may require prompt medical attention.
Diagnosis of Haemophilus Infections:
* Diagnostic tests: diagnosis of Hib disease is based on a combination of clinical findings, laboratory tests, and radiologic studies. Blood cultures, lumbar puncture, and chest x-rays may be used to confirm the presence of the bacteria and assess the extent of infection.
* Laboratory testing: identification of Hib is based on its distinctive gram stain appearance and biochemical characteristics. Polymerase chain reaction (PCR) and DNA sequencing are also used to confirm the diagnosis.
Treatment and Prevention of Haemophilus Infections:
* Antibiotics: Hib infections are treated with antibiotics, such as amoxicillin or ceftriaxone. The choice of antibiotic depends on the severity and location of the infection.
* Vaccination: the Hib vaccine is recommended for children under 5 years old to prevent Hib disease. The vaccine is given in a series of 3-4 doses, with the first dose given at 2 months of age.
* Good hygiene practices: good hygiene practices, such as frequent handwashing and proper cleaning and disinfection, can help prevent the spread of Hib bacteria.
Complications of Haemophilus Infections:
* Meningitis: Hib meningitis can have serious complications, including hearing loss, learning disabilities, and seizures.
* Permanent brain damage: Hib infections can cause permanent brain damage, including cognitive and behavioral impairments.
* Respiratory failure: severe Hib pneumonia can lead to respiratory failure, which may require mechanical ventilation.
* Death: Hib infections can be life-threatening, especially in young children and those with underlying medical conditions.
In conclusion, Haemophilus infections are a serious public health concern, particularly for young children and those with underlying medical conditions. Prevention through vaccination and good hygiene practices is essential to reduce the risk of infection. Early diagnosis and treatment are critical to prevent complications and improve outcomes.
Symptoms of epiglottitis may include:
* Sudden onset of sore throat
* Fever
* Difficulty swallowing
* Hoarseness or a "barky" cough
* Pain with swallowing
* Enlarged tonsils
* Swollen lymph nodes in the neck
In severe cases, epiglottitis can lead to:
* Airway obstruction
* Respiratory failure
Treatment of epiglottitis typically involves antibiotics for bacterial infections and supportive care such as fluids, oxygen therapy, and pain management. In severe cases, surgical intervention may be necessary to remove the affected tissue.
Prevention of epiglottitis includes:
* Good hand washing practices
* Avoiding close contact with people who are sick
* Keeping up to date on vaccinations
* Practicing safe oral hygiene
It is important to seek medical attention immediately if symptoms of epiglottitis develop, as prompt treatment can help prevent serious complications.
Symptoms of meningitis may include fever, headache, stiff neck, confusion, nausea and vomiting, and sensitivity to light. In severe cases, it can lead to seizures, brain damage, and even death.
There are several types of meningitis, including:
1. Viral meningitis: This is the most common form of the infection and is usually caused by enteroviruses or herpesviruses. It is typically less severe than bacterial meningitis and resolves on its own with supportive care.
2. Bacterial meningitis: This is a more serious form of the infection and can be caused by a variety of bacteria, such as Streptococcus pneumoniae, Neisseria meningitidis, and Haemophilus influenzae. It requires prompt antibiotic treatment to prevent long-term complications and death.
3. Fungal meningitis: This type of meningitis is more common in people with weakened immune systems and is caused by fungi that are commonly found in the environment. It can be treated with antifungal medications.
4. Parasitic meningitis: This type of meningitis is rare and is caused by parasites that are typically found in tropical regions. It can be treated with antiparasitic medications.
Diagnosis of meningitis is based on a combination of clinical findings, laboratory tests, and imaging studies. Laboratory tests may include blood cultures, polymerase chain reaction (PCR) testing, and cerebrospinal fluid (CSF) analysis. Imaging studies, such as CT or MRI scans, may be used to rule out other conditions and to evaluate the extent of brain damage.
Treatment of meningitis depends on the cause of the infection and may include antibiotics, antiviral medications, antifungal medications, or supportive care to manage symptoms and prevent complications. Supportive care may include intravenous fluids, oxygen therapy, and pain management. In severe cases, meningitis may require hospitalization in an intensive care unit (ICU) and may result in long-term consequences such as hearing loss, learning disabilities, or cognitive impairment.
Prevention of meningitis includes vaccination against the bacteria or viruses that can cause the infection, good hygiene practices, and avoiding close contact with people who are sick. Vaccines are available for certain types of meningitis, such as the meningococcal conjugate vaccine (MenACWY) and the pneumococcal conjugate vaccine (PCV). Good hygiene practices include washing hands frequently, covering the mouth and nose when coughing or sneezing, and avoiding sharing food, drinks, or personal items.
In conclusion, meningitis is a serious and potentially life-threatening infection that can affect people of all ages. Early diagnosis and treatment are crucial to prevent long-term consequences and improve outcomes. Prevention includes vaccination, good hygiene practices, and avoiding close contact with people who are sick.
Symptoms of bacterial meningitis may include sudden onset of fever, headache, stiff neck, nausea, vomiting, and sensitivity to light. In severe cases, the infection can cause seizures, coma, and even death.
Bacterial meningitis can be diagnosed through a combination of physical examination, laboratory tests, and imaging studies such as CT or MRI scans. Treatment typically involves antibiotics to eradicate the infection, and supportive care to manage symptoms and prevent complications.
Early diagnosis and treatment are critical to prevent long-term damage and improve outcomes for patients with bacterial meningitis. The disease is more common in certain groups, such as infants, young children, and people with weakened immune systems, and it can be more severe in these populations.
Prevention of bacterial meningitis includes vaccination against the bacteria that most commonly cause the disease, good hand hygiene, and avoiding close contact with people who are sick.
Definition: Meningitis, pneumococcal, is an inflammatory disease caused by Streptococcus pneumoniae (pneumococcus) that affects the protective membranes (meninges) covering the brain and spinal cord, leading to a range of symptoms including fever, headache, vomiting, and altered mental status. It can be a severe and potentially life-threatening infection, particularly in certain patient populations such as children under 5 years old, older adults, and those with underlying medical conditions.
Epidemiology: Pneumococcal meningitis is relatively uncommon, but it remains an important public health concern, particularly in developed countries. According to the Centers for Disease Control and Prevention (CDC), there are approximately 350 cases of pneumococcal meningitis reported each year in the United States, resulting in about 10% of all cases of bacterial meningitis.
Risk Factors: Several risk factors have been identified for developing pneumococcal meningitis, including:
1. Age: Children under 5 years old and older adults are at increased risk.
2. Underlying medical conditions: Patients with conditions such as sickle cell disease, HIV/AIDS, and chronic lung disease are more likely to develop pneumococcal meningitis.
3. Weakened immune system: Those with compromised immune systems, such as those taking immunosuppressive medications or who have undergone organ transplants, are at higher risk.
4. Recent exposure to someone with pneumococcal disease: Close contact with someone who has recently been diagnosed with pneumococcal disease can increase the risk of developing the infection.
Clinical Presentation: Symptoms of pneumococcal meningitis can vary depending on the age of the patient, but common presentations include:
1. Fever
2. Headache
3. Vomiting
4. Altered mental status (in infants and young children) or confusion (in older adults)
5. Stiff neck
6. Sensitivity to light (photophobia)
7. Bulging of the soft spots on the skull in infants (in infants)
Diagnosis: The diagnosis of pneumococcal meningitis is based on a combination of clinical findings, laboratory tests, and imaging studies. Laboratory tests may include blood cultures, cerebrospinal fluid (CSF) cultures, and polymerase chain reaction (PCR) to detect the presence of S. pneumoniae. Imaging studies, such as CT or MRI scans, may be used to evaluate the brain and identify any signs of inflammation or abscesses.
Treatment: Pneumococcal meningitis is typically treated with antibiotics, which are usually given intravenously. The choice of antibiotic depends on the severity of the infection and the patient's age and medical history. In addition to antibiotics, supportive care may be provided to manage symptoms such as fever, headache, and muscle aches. In severe cases, hospitalization may be necessary to monitor and treat the infection.
Complications: Pneumococcal meningitis can lead to serious complications, including:
1. Hearing loss
2. Learning disabilities
3. Behavioral changes
4. Seizures
5. Brain damage
6. Death
Prevention: Pneumococcal conjugate vaccine (PCV) is recommended for children under the age of 2 years and for certain high-risk groups, such as adults over the age of 65 and people with certain medical conditions. The vaccine can help prevent pneumococcal meningitis and other serious infections caused by S. pneumoniae. Good hygiene practices, such as frequent handwashing, can also help prevent the spread of the bacteria.
Prognosis: With prompt and appropriate treatment, the prognosis for pneumococcal meningitis is generally good. However, in severe cases or those with complications, the prognosis may be poorer. In some cases, long-term sequelae such as hearing loss, learning disabilities, and behavioral changes may occur.
Incubation period: The incubation period for pneumococcal meningitis is typically between 2 and 4 days, but it can range from 1 to 10 days.
Diagnosis: Pneumococcal meningitis is diagnosed based on a combination of clinical symptoms, physical examination findings, laboratory tests, and imaging studies such as CT or MRI scans. Laboratory tests may include blood cultures, cerebrospinal fluid (CSF) analysis, and PCR testing to identify the presence of S. pneumoniae.
Treatment: Treatment for pneumococcal meningitis typically involves antibiotics and supportive care to manage symptoms such as fever, headache, and muscle aches. In severe cases, hospitalization may be necessary to monitor and treat the infection.
In conclusion, pneumococcal meningitis is a serious infection that can cause significant morbidity and mortality. Prompt diagnosis and appropriate treatment are essential to prevent long-term sequelae and improve outcomes for affected individuals.
Symptoms of meningococcal meningitis typically develop within 3-7 days after exposure and may include fever, headache, stiff neck, confusion, nausea and vomiting, sensitivity to light, and seizures. In severe cases, the infection can lead to shock, organ failure, and death within hours of the onset of symptoms.
Diagnosis is typically made by a combination of physical examination, laboratory tests (such as blood cultures and PCR), and imaging studies (such as CT or MRI scans). Treatment typically involves antibiotics, intravenous fluids, and supportive care to manage fever, pain, and other symptoms. In severe cases, hospitalization in an intensive care unit may be necessary.
Prevention of meningococcal meningitis includes the use of vaccines, good hygiene practices (such as frequent handwashing), and avoidance of close contact with people who are sick. A vaccine is available for children and teens, and some colleges and universities require students to be vaccinated before moving into dorms.
Early diagnosis and treatment are crucial in preventing long-term complications and reducing the risk of death from meningococcal meningitis. If you suspect that you or someone else may have meningococcal meningitis, it is important to seek medical attention immediately.
* Earache (otalgia)
* Fever
* Hearing loss or muffled hearing
* Discharge from the ear
* Redness and swelling around the ear drum
* Fussiness or irritability in infants
* Loss of appetite or difficulty eating
* Difficulty sleeping
Otitis media is caused by a virus or bacteria that enters the middle ear through the Eustachian tube, which connects the back of the throat to the middle ear. The infection can spread quickly and cause inflammation in the middle ear, leading to hearing loss and other symptoms.
There are several types of otitis media, including:
* Acute otitis media: This is a sudden and severe infection that can develop over a few days. It is usually caused by a bacterial infection and can be treated with antibiotics.
* Otitis media with effusion (OME): This is a condition where fluid accumulates in the middle ear without an infection present. It can cause hearing loss and other symptoms but does not respond to antibiotics.
* Chronic suppurative otitis media (CSOM): This is a long-term infection that can cause persistent discharge, hearing loss, and other symptoms. It may require ongoing treatment with antibiotics and other therapies.
Otitis media can be diagnosed through a physical examination of the ear and a review of the patient's medical history. A doctor may also use tests such as a tympanocentesis (insertion of a small tube into the ear to collect fluid) or an otoscopic exam to confirm the diagnosis.
Treatment for otitis media depends on the type and severity of the infection, but may include:
* Antibiotics: To treat bacterial infections
* Pain relief medication: To help manage ear pain and fever
* Eardrops: To help clear fluid from the middle ear and reduce discharge
* Tympanocentesis: To collect fluid from the middle ear for testing or to relieve pressure
* Ventilation tubes: Small tubes that are inserted into the ear drum to allow air to enter the middle ear and help drain fluid.
It is important to seek medical attention if symptoms of otitis media persist or worsen over time, as untreated infections can lead to complications such as mastoiditis (an infection of the bones behind the ear) or meningitis (an infection of the lining around the brain and spinal cord). With prompt and appropriate treatment, however, most cases of otitis media can be effectively managed and hearing loss can be prevented.
Here are some key points to define sepsis:
1. Inflammatory response: Sepsis is characterized by an excessive and uncontrolled inflammatory response to an infection. This can lead to tissue damage and organ dysfunction.
2. Systemic symptoms: Patients with sepsis often have systemic symptoms such as fever, chills, rapid heart rate, and confusion. They may also experience nausea, vomiting, and diarrhea.
3. Organ dysfunction: Sepsis can cause dysfunction in multiple organs, including the lungs, kidneys, liver, and heart. This can lead to organ failure and death if not treated promptly.
4. Infection source: Sepsis is usually caused by a bacterial infection, but it can also be caused by fungal or viral infections. The infection can be localized or widespread, and it can affect different parts of the body.
5. Severe sepsis: Severe sepsis is a more severe form of sepsis that is characterized by severe organ dysfunction and a higher risk of death. Patients with severe sepsis may require intensive care unit (ICU) admission and mechanical ventilation.
6. Septic shock: Septic shock is a life-threatening condition that occurs when there is severe circulatory dysfunction due to sepsis. It is characterized by hypotension, vasopressor use, and organ failure.
Early recognition and treatment of sepsis are critical to preventing serious complications and improving outcomes. The Sepsis-3 definition is widely used in clinical practice to diagnose sepsis and severe sepsis.
The symptoms of tetanus can develop anywhere from 3 days to 3 weeks after exposure to the bacteria, and they can include:
* Muscle stiffness and spasms, especially in the neck, jaw, and limbs
* Difficulty swallowing or speaking
* Fever and sweating
* Headache and fatigue
* Rigidity and spasticity of muscles
* Abdominal cramps and diarrhea
* In severe cases, tetanus can cause serious complications such as pneumonia, heart problems, and death.
Tetanus is diagnosed through a physical examination, medical history, and laboratory tests. Treatment typically involves administering antitoxin medication to neutralize the effects of the bacterial toxins, as well as providing supportive care such as pain management and wound care.
Prevention is key in avoiding tetanus, and this can be achieved through:
* Vaccination: Tetanus vaccines are available and recommended for individuals of all ages, especially for those who have open wounds or injuries.
* Proper wound care: Keeping wounds clean and covered can help prevent the entry of bacteria into the body.
* Avoiding risky behaviors: Avoiding activities that can cause injury, such as playing contact sports or engaging in dangerous hobbies, can reduce the risk of developing tetanus.
Overall, tetanus is a serious medical condition that requires prompt treatment and prevention measures to avoid complications and ensure a full recovery.
The cause of panophthalmitis is often related to bacterial infections, such as endophthalmitis, which is an infection within the eyeball, or orbital cellulitis, which is an infection of the tissues surrounding the eye. Other causes may include trauma to the eye, foreign body lodged in the eye, or systemic infections such as meningitis or sepsis.
Symptoms of panophthalmitis may include:
* Severe pain and redness of the eye
* Swelling of the eyelids and eye ball
* Sensitivity to light
* Blurred vision or vision loss
* Fever, chills, and general feeling of being unwell
* Difficulty moving the eyes or facial paralysis
Diagnosis of panophthalmitis is based on a combination of physical examination, medical history, and laboratory tests such as blood cultures, PCR, and imaging studies like CT or MRI.
Treatment of panophthalmitis usually involves antibiotics to combat any underlying infection, and management of symptoms such as pain and inflammation. In some cases, surgical intervention may be necessary to drain abscesses or remove foreign bodies from the eye.
Prognosis for panophthalmitis is generally poor, with a high risk of complications such as blindness, cranial nerve palsies, and extracapsular cataract formation. Prompt treatment and management are essential to prevent further damage and improve outcomes.
The symptoms of diphtheria typically develop within 2-5 days after exposure and may include:
* Sore throat and difficulty swallowing
* Fever and chills
* Swollen and tender lymph nodes in the neck
* Difficulty breathing or shortness of breath
* Skin lesions or rashes
* Nerve damage, leading to weakness, paralysis, and other neurological symptoms.
If left untreated, diphtheria can lead to serious complications such as respiratory failure, heart failure, and death. Treatment typically involves antibiotics, which can help clear the infection and prevent further damage. In severe cases, hospitalization may be required to provide supportive care, such as mechanical ventilation or cardiac support.
Diphtheria is a vaccine-preventable disease, and immunization programs have been instrumental in reducing the incidence of this disease worldwide. However, outbreaks still occur in some areas, particularly among unvaccinated individuals or those living in areas with low vaccination coverage.
In addition to its clinical features, diphtheria has several key characteristics that are important to note:
* It is highly contagious and can be transmitted through respiratory droplets, close contact with an infected person, or by touching contaminated surfaces and objects.
* The bacteria can survive for weeks outside the body, making it a significant risk for transmission through fomites.
* Immunity to diphtheria is not lifelong, and booster doses of the vaccine are recommended every 10 years to maintain protection.
Types of Pneumococcal Infections:
1. Pneumonia: This is an infection of the lungs that can cause fever, cough, chest pain, and difficulty breathing.
2. Meningitis: This is an infection of the membranes that cover the brain and spinal cord, which can cause fever, headache, stiff neck, and confusion.
3. Septicemia (bloodstream infection): This is an infection of the blood that can cause fever, chills, and low blood pressure.
4. Sinusitis: This is an infection of the sinuses, which can cause headache, facial pain, and difficulty breathing through the nose.
5. Otitis media (middle ear infection): This is an infection of the middle ear, which can cause ear pain, fever, and hearing loss.
Causes and Risk Factors:
Pneumococcal infections are caused by the bacteria Streptococcus pneumoniae. These bacteria can be spread through close contact with an infected person, such as touching or sharing food and drinks. People who are at high risk for developing pneumococcal infections include:
1. Children under the age of 5 and adults over the age of 65.
2. People with weakened immune systems, such as those with cancer, HIV/AIDS, or taking medications that suppress the immune system.
3. Smokers and people with chronic respiratory diseases, such as asthma or chronic obstructive pulmonary disease (COPD).
4. People who have recently had surgery or have a severe injury.
5. Those who live in long-term care facilities or have limited access to healthcare.
Prevention and Treatment:
Preventing pneumococcal infections is important, especially for high-risk individuals. Here are some ways to prevent and treat pneumococcal infections:
1. Vaccination: The pneumococcal conjugate vaccine (PCV) is recommended for children under the age of 5 and adults over the age of 65, as well as for people with certain medical conditions.
2. Hand washing: Frequent hand washing can help prevent the spread of pneumococcal bacteria.
3. Good hygiene: Avoiding close contact with people who are sick and regularly cleaning surfaces that may be contaminated with bacteria can also help prevent infection.
4. Antibiotics: Pneumococcal infections can be treated with antibiotics, but overuse of antibiotics can lead to the development of antibiotic-resistant bacteria. Therefore, antibiotics should only be used when necessary and under the guidance of a healthcare professional.
5. Supportive care: Those with severe pneumococcal infections may require hospitalization and supportive care, such as oxygen therapy or mechanical ventilation.
Conclusion:
Pneumococcal infections can be serious and even life-threatening, especially for high-risk individuals. Prevention and prompt treatment are key to reducing the risk of complications and improving outcomes. Vaccination, good hygiene practices, and appropriate antibiotic use are all important in preventing and treating pneumococcal infections. If you suspect that you or a loved one has a pneumococcal infection, it is essential to seek medical attention right away. With proper care and support, many people with pneumococcal infections can recover fully and resume their normal lives.
The most common bacteria that cause pneumonia are Streptococcus pneumoniae (also known as pneumococcus), Haemophilus influenzae, and Staphylococcus aureus. These bacteria can infect the lungs through various routes, including respiratory droplets, contaminated food or water, or direct contact with an infected person.
Symptoms of pneumonia may include cough, fever, chills, shortness of breath, and chest pain. In severe cases, pneumonia can lead to serious complications such as respiratory failure, sepsis, and death.
Diagnosis of pneumonia typically involves a physical examination, medical history, and diagnostic tests such as chest X-rays or blood cultures. Treatment typically involves antibiotics to eliminate the infection, as well as supportive care to manage symptoms and prevent complications. Vaccines are also available to protect against certain types of bacterial pneumonia, particularly in children and older adults.
Preventative measures for bacterial pneumonia include:
* Getting vaccinated against Streptococcus pneumoniae and Haemophilus influenzae type b (Hib)
* Practicing good hygiene, such as washing hands regularly and covering the mouth and nose when coughing or sneezing
* Avoiding close contact with people who are sick
* Staying hydrated and getting enough rest
* Quitting smoking, if applicable
* Managing underlying medical conditions, such as diabetes or heart disease
It is important to seek medical attention promptly if symptoms of pneumonia develop, particularly in high-risk populations. Early diagnosis and treatment can help prevent serious complications and improve outcomes for patients with bacterial pneumonia.
Symptoms of pneumococcal pneumonia can include fever, cough, chest pain, shortness of breath, and difficulty breathing. In severe cases, the infection can spread to the bloodstream and cause sepsis, a life-threatening condition that requires immediate medical attention.
Pneumococcal pneumonia is most commonly seen in young children, older adults, and people with weakened immune systems, such as those with cancer, HIV/AIDS, or taking immunosuppressive medications. It is usually diagnosed through a combination of physical examination, medical history, and diagnostic tests such as chest X-rays and blood cultures.
Treatment of pneumococcal pneumonia typically involves antibiotics to eliminate the bacterial infection. In severe cases, hospitalization may be necessary to provide oxygen therapy, fluid replacement, and other supportive care. Vaccines are also available to prevent Streptococcus pneumoniae infections, particularly in children and older adults.
Prevention measures for pneumococcal pneumonia include:
* Vaccination: The pneumococcal conjugate vaccine (PCV) is recommended for children under the age of 2 and older adults over the age of 65, as well as for people with certain medical conditions.
* Good hygiene: Regular handwashing and avoiding close contact with people who are sick can help prevent the spread of the infection.
* Avoiding smoking: Smoking can damage the lungs and increase the risk of infection.
* Keeping up-to-date on recommended vaccinations: Staying current on recommended vaccinations, such as the flu shot, can help prevent secondary bacterial infections like pneumococcal pneumonia.
* Managing underlying conditions: People with certain medical conditions, such as diabetes or chronic lung disease, should work with their healthcare provider to manage their condition and reduce their risk of developing pneumococcal pneumonia.
It's important to seek medical attention right away if you or someone you know is experiencing symptoms of pneumococcal pneumonia, as early treatment can help prevent complications and improve outcomes.
Bacteremia can occur when bacteria enter the bloodstream through various means, such as:
* Infected wounds or surgical sites
* Injecting drug use
* Skin infections
* Respiratory tract infections
* Urinary tract infections
* Endocarditis (infection of the heart valves)
The symptoms of bacteremia can vary depending on the type of bacteria and the severity of the infection. Some common symptoms include:
* Fever
* Chills
* Headache
* Muscle aches
* Weakness
* Confusion
* Shortness of breath
Bacteremia is diagnosed by blood cultures, which involve collecting blood samples and inserting them into a specialized container to grow the bacteria. Treatment typically involves antibiotics and supportive care, such as intravenous fluids and oxygen therapy. In severe cases, hospitalization may be necessary to monitor and treat the infection.
Prevention measures for bacteremia include:
* Practicing good hygiene, such as washing hands regularly
* Avoiding sharing personal items like toothbrushes or razors
* Properly cleaning and covering wounds
* Getting vaccinated against infections that can lead to bacteremia
* Following proper sterilization techniques during medical procedures
Overall, bacteremia is a serious condition that requires prompt medical attention to prevent complications and ensure effective treatment.
1. Platelet disorders: These include conditions such as idiopathic thrombocytopenic purpura (ITP), where the immune system attacks and destroys platelets, leading to a low platelet count and bleeding symptoms.
2. Von Willebrand disease: This is a bleeding disorder caused by a deficiency of von Willebrand factor, a protein that helps platelets stick together and form clots.
3. Hemophilia A and B: These are genetic disorders that affect the blood's ability to clot and stop bleeding.
4. Vitamin K-dependent bleeding disorders: These include conditions such as vitamin K-dependent coagulopathy, which is caused by a deficiency of vitamin K and leads to abnormal clotting and bleeding.
5. Other causes: Purpura can also be caused by other medical conditions, such as liver disease, kidney disease, and certain medications.
The symptoms of purpura can vary depending on the underlying cause, but may include:
* Easy bruising (especially on the skin and joints)
* Petechiae (small red or purple spots on the skin)
* Prolonged bleeding from injuries or surgical sites
* Nosebleeds
* Gingival bleeding (bleeding from the gums)
* Heavy menstrual periods
* Bleeding into joints and muscles
If you suspect that you or someone else may have purpura, it is important to seek medical attention as soon as possible. A healthcare professional will perform a physical examination and order laboratory tests to determine the underlying cause of the bleeding disorder. Treatment for purpura depends on the specific cause, but may include medications to increase platelet count or clotting factor, or surgery to correct an underlying condition.
Some common examples of bacterial infections include:
1. Urinary tract infections (UTIs)
2. Respiratory infections such as pneumonia and bronchitis
3. Skin infections such as cellulitis and abscesses
4. Bone and joint infections such as osteomyelitis
5. Infected wounds or burns
6. Sexually transmitted infections (STIs) such as chlamydia and gonorrhea
7. Food poisoning caused by bacteria such as salmonella and E. coli.
In severe cases, bacterial infections can lead to life-threatening complications such as sepsis or blood poisoning. It is important to seek medical attention if symptoms persist or worsen over time. Proper diagnosis and treatment can help prevent these complications and ensure a full recovery.
The common types of RTIs include:
1. Common cold: A viral infection that affects the upper respiratory tract, causing symptoms such as runny nose, sneezing, coughing, and mild fever.
2. Influenza (flu): A viral infection that can affect both the upper and lower respiratory tract, causing symptoms such as fever, cough, sore throat, and body aches.
3. Bronchitis: An inflammation of the bronchial tubes, which can be caused by viruses or bacteria, resulting in symptoms such as coughing, wheezing, and shortness of breath.
4. Pneumonia: An infection of the lungs that can be caused by bacteria, viruses, or fungi, leading to symptoms such as fever, chills, coughing, and difficulty breathing.
5. Tonsillitis: An inflammation of the tonsils, which can be caused by bacteria or viruses, resulting in symptoms such as sore throat, difficulty swallowing, and bad breath.
6. Sinusitis: An inflammation of the sinuses, which can be caused by viruses, bacteria, or fungi, leading to symptoms such as headache, facial pain, and nasal congestion.
7. Laryngitis: An inflammation of the larynx (voice box), which can be caused by viruses or bacteria, resulting in symptoms such as hoarseness, loss of voice, and difficulty speaking.
RTIs can be diagnosed through physical examination, medical history, and diagnostic tests such as chest X-rays, blood tests, and nasal swab cultures. Treatment for RTIs depends on the underlying cause and may include antibiotics, antiviral medications, and supportive care to manage symptoms.
It's important to note that RTIs can be contagious and can spread through contact with an infected person or by touching contaminated surfaces. Therefore, it's essential to practice good hygiene, such as washing hands frequently, covering the mouth and nose when coughing or sneezing, and avoiding close contact with people who are sick.
Symptoms of chancroid include:
1. Painful ulcers on the genitalia, anus, or mouth
2. Swollen lymph nodes in the groin
3. Fever
4. Headache
5. Fatigue
6. Painful urination
Diagnosis of chancroid is based on physical examination and laboratory tests, such as a wet preparation or culture. Treatment involves antibiotics, and early treatment can help prevent complications. It is important to seek medical attention if symptoms persist or worsen over time. Prevention strategies include safe sex practices, such as using condoms, and regular testing for sexually transmitted infections.
Note: Chancroid is a relatively rare infection in developed countries, but it is still important to be aware of the risk factors and symptoms, especially if you have multiple sexual partners or engage in unprotected sex.
Symptoms of whooping cough typically appear within 7-14 days after exposure and may include:
* Mild fever
* Runny nose
* Sneezing
* Dry, irritating cough that progresses to spasmodic, convulsive coughing fits
* Vomiting after coughing
* Apnea (pause in breathing)
In infants, the symptoms may be milder and include:
* Mild fever
* Lack of appetite
* Irritability
* Cyanosis (blue discoloration of the skin)
If left untreated, whooping cough can lead to serious complications such as pneumonia, seizures, and brain damage. Diagnosis is based on a combination of clinical findings, laboratory tests, and medical imaging. Treatment typically involves antibiotics and supportive care to manage symptoms and prevent complications.
Prevention measures include immunization with the pertussis vaccine, which is routinely given to infants and children in early childhood, as well as booster shots during adolescence and adulthood. Good hygiene practices, such as frequent handwashing and avoiding close contact with people who are sick, can also help prevent the spread of the disease.
Symptoms of pneumonia may include cough, fever, chills, difficulty breathing, and chest pain. In severe cases, pneumonia can lead to respiratory failure, sepsis, and even death.
There are several types of pneumonia, including:
1. Community-acquired pneumonia (CAP): This type of pneumonia is caused by bacteria or viruses and typically affects healthy people outside of hospitals.
2. Hospital-acquired pneumonia (HAP): This type of pneumonia is caused by bacteria or fungi and typically affects people who are hospitalized for other illnesses or injuries.
3. Aspiration pneumonia: This type of pneumonia is caused by food, liquids, or other foreign matter being inhaled into the lungs.
4. Pneumocystis pneumonia (PCP): This type of pneumonia is caused by a fungus and typically affects people with weakened immune systems, such as those with HIV/AIDS.
5. Viral pneumonia: This type of pneumonia is caused by viruses and can be more common in children and young adults.
Pneumonia is typically diagnosed through a combination of physical examination, medical history, and diagnostic tests such as chest X-rays or blood tests. Treatment may involve antibiotics, oxygen therapy, and supportive care to manage symptoms and help the patient recover. In severe cases, hospitalization may be necessary to provide more intensive care and monitoring.
Prevention of pneumonia includes vaccination against certain types of bacteria and viruses, good hygiene practices such as frequent handwashing, and avoiding close contact with people who are sick. Early detection and treatment can help reduce the risk of complications and improve outcomes for those affected by pneumonia.
Moraxellaceae infections are typically caused by the bacteria entering the body through a break in the skin or mucous membranes, such as during a cut or scratch. Once inside the body, the bacteria can multiply and cause inflammation and damage to surrounding tissues.
The symptoms of Moraxellaceae infections can vary depending on the location and severity of the infection. Some common symptoms include:
* Fever
* Cough
* Shortness of breath
* Chest pain
* Skin redness and swelling
* Pus-filled abscesses or boils
Moraxellaceae infections can be diagnosed through a variety of tests, including blood cultures, respiratory secretion testing, and skin scrapings. Treatment typically involves antibiotics to kill the bacteria and clear up the infection. In severe cases, hospitalization may be necessary to provide more intensive treatment and monitoring.
Preventing Moraxellaceae infections can be challenging, but some steps that can help include:
* Practicing good hygiene, such as washing your hands regularly and avoiding close contact with people who are sick
* Avoiding sharing personal items, such as towels or razors, with others
* Covering wounds and cuts to prevent bacteria from entering the body
* Keeping vaccinations up to date, as some types of Moraxellaceae infections can be prevented by vaccination.
Overall, Moraxellaceae infections can be serious and potentially life-threatening, so it's important to seek medical attention if you suspect that you or someone else may have an infection. With prompt and appropriate treatment, however, most people with Moraxellaceae infections can recover fully.
Ear Anatomy: The middle ear consists of three small bones called ossicles (the malleus, incus, and stapes) that transmit sound waves to the inner ear. The eardrum, a thin membrane, separates the outer ear canal from the middle ear. In OME, fluid accumulates in the middle ear, causing the eardrum to become congested and reducing its ability to vibrate properly.
Causes: There are several factors that can contribute to the development of OME, including:
1. Viral upper respiratory infections (such as the common cold)
2. Allergies
3. Enlarged adenoids or tonsils
4. Cystic fibrosis
5. Sinus infections
6. Meniere's disease
7. Head injury
Symptoms: The symptoms of OME can vary depending on the severity of the condition, but may include:
1. Hearing loss or muffled hearing
2. Discharge or fluid leaking from the ear
3. Pain or discomfort in the ear
4. Difficulty responding to sounds or understanding speech
5. Fever
6. Headache
7. Vertigo or dizziness
8. Loss of balance or coordination
Diagnosis: OME is typically diagnosed through a combination of physical examination, medical history, and ear examinations using an otoscope or tympanometry. A tympanogram may also be performed to measure the movement of the eardrum.
Treatment: The treatment of OME depends on the severity of the condition and may include:
1. Watchful waiting: In mild cases, OME may resolve on its own within a few weeks without any treatment.
2. Antibiotics: If there is a concurrent infection, antibiotics may be prescribed to treat the underlying infection.
3. Pain relief medication: Over-the-counter pain relief medication such as acetaminophen or ibuprofen may be recommended to relieve any discomfort or pain.
4. Eardrops: Eardrops containing antibiotics or steroids may be prescribed to treat the infection and reduce inflammation.
5. Tubes in the ear: In more severe cases, tubes may be placed in the ear drum to help drain fluid and relieve pressure.
6. Surgery: In rare cases, surgery may be necessary to remove the membrane or repair any damage to the middle ear bones.
Prognosis: The prognosis for OME is generally good, with most cases resolving within a few weeks without any long-term complications. However, in some cases, the condition can persist for longer periods of time and may lead to more serious complications such as hearing loss or mastoiditis.
Prevention: There is no specific way to prevent OME, but good ear hygiene and avoiding exposure to loud noises can help reduce the risk of developing the condition. Regular check-ups with an audiologist or otolaryngologist can also help identify any early signs of OME and prevent complications.
Conclusion: Otitis media with effusion (OME) is a common condition that affects children and adults, causing fluid buildup in the middle ear. While it is generally not a serious condition, it can cause discomfort and affect hearing. Treatment options range from watchful waiting to antibiotics and surgery, depending on the severity of the case. Good ear hygiene and regular check-ups with an audiologist or otolaryngologist can help prevent complications and ensure proper management of the condition.
Haemophilus influenzae
Uptake signal sequence
Katherine O'Brien
Epiglottitis
Vaccine
Hib vaccine
Hospital-acquired pneumonia
Haemophilus meningitis
Epiglottis
Bacterial cellular morphologies
Childhood immunizations in the United States
Neal Halsey
Coccobacillus
Herd immunity
Lois Privor-Dumm
Stephanie Factor
George Siber
Asplenia
Septic arthritis
Sentinel surveillance
Nicotinamide adenine dinucleotide
N-glycosyltransferase
Samir Kumar Saha
Claire V. Broome
Conjugate vaccine
Chandrakant Lahariya
Waterhouse-Friderichsen syndrome
J. Bart Classen
Pneumonia
Haemophilus influenzae biogroup aegyptius
Porter W Anderson Jr.
Pegcetacoplan
Trimeric autotransporter adhesin
Aspiration pneumonia
Hugh Pennington
Door handle bacteria
Histophilus somni
Vaccine hesitancy
CLEC7A
Atypical pneumonia
Influenza
Sheldon H. Jacobson
List of skin conditions
Medical microbiology
Hypothiocyanite
DUSP1
Polio vaccine
Diffuse panbronchiolitis
Medical Research Club
Piperacillin
Panacea Biotec
Vaginitis
Tetanus vaccine
Gram-negative bacteria
Haemophilus influenzae: Types of Infection | CDC
Haemophilus influenzae type b (Hib) Vaccine: MedlinePlus Drug Information
Browsing by Subject "Haemophilus influenzae type b"
DailyMed - ACTHIB- haemophilus influenzae type b strain 1482 capsular polysaccharide tetanus toxoid conjugate antigen kit
WHO EMRO | Haemophilus influenzae type B | Health topics
Invasive Type e Haemophilus influenzae Disease in Italy - Volume 9, Number 2-February 2003 - Emerging Infectious Diseases...
Global literature review of Haemophilus influenzae type b and Streptococcus pneumoniae invasive disease among children less...
Global literature review of Haemophilus influenzae type b and Streptococcus pneumoniae invasive disease among children less...
MedlinePlus - Search Results for: HAEMOPHILUS INFLUENZAE TYPE B STRAIN 1482 CAPSULAR POLYSACCHARIDE TETANUS TOXOID CONJUGATE...
Adverse events following Haemophilus influenzae type b vaccines in the Vaccine Adverse Event Reporting System, 1990-2013
ActHIB, Hiberix (haemophilus influenzae type b vaccine) dosing, indications, interactions, adverse effects, and more
9 Haemophilus influenzae Type b Vaccines | Adverse Events Associated with Childhood Vaccines: Evidence Bearing on Causality ...
Haemophilus influenzae type b (Hib3) vaccination coverage
Impact of Haemophilus influenzae Type b conjugate vaccine in Mongolia: prospective population-based surveillance, 2002-2010. |...
Number of new Haemophilus influenzae type b invasive disease cases - European Health Information Gateway
API | haemophilus influenzae type b conjugate vaccine
DailyMed - ACTHIB- haemophilus influenzae type b strain 1482 capsular polysaccharide tetanus toxoid conjugate antigen kit
ChildVaxView | 2017 Childhood Hib Vaccination Coverage Dashboard | CDC
Disease Prevention Toolkit | National Institutes of Health (NIH)
Influenza: High-Dose Vaccine Decreases Flu in Older Adults
A study of Physico-Chemical Interactions between Haemophilus Influenzae Type b and Meningococcus group C Conjugate Vaccines |...
ACIP: General Recommendations on Immunization
More than medical care: EMEDS prescribes hope | Health.mil
Safeguarding Our Health | NIH News in Health
Medicine
Polysaccharide6
- We studied an immunogen consisting of oligosaccharides derived from Haemophilus influenzae type b capsular polysaccharide (PRP) coupled to CRM197, a nontoxic relative of diphtheria toxin. (nih.gov)
- Safety and immunogenicity of Haemophilus influenzae type b-polysaccharide diphtheria toxoid conjugate vaccine in infants 9 to 15 months of age. (nih.gov)
- Haemophilus influenzae is an aerobic gram-negative bacteria with a polysaccharide capsule with six different serotypes (a-f) of polysaccharide capsule. (freece.com)
- 1985). Nearly 75 percent of cases of Hib disease occurred in children younger than 2 years of age, and the susceptibility of young children to infection with Hib correlated with their lack of antibody to the type b capsular polysaccharide, polyribosylribitol phosphate (PRP) (Ward and Cochi, 1988). (nationalacademies.org)
- Thus, in consideration of the side effects of Hib conjugate vaccines, it is plausible that variations in the type or frequency of adverse effects may occur because of differences in the polysaccharide or protein components of the vaccines. (nationalacademies.org)
- Invasive disease caused by the encapsulated bacteria Neisseria meningitidis, Haemophilus influenzae and Streptococcus pneumoniae remains an important cause of morbidity and mortality worldwide, despite the introduction of successful conjugate polysaccharide vaccines that target disease-associated strains. (ox.ac.uk)
Vaccine19
- Hib vaccine can prevent Haemophilus influenzae type b (Hib) disease . (medlineplus.gov)
- Hib vaccine may be given as a stand-alone vaccine, or as part of a combination vaccine (a type of vaccine that combines more than one vaccine together into one shot). (medlineplus.gov)
- ActHIB is a vaccine indicated for the prevention of invasive disease caused by Haemophilus influenzae type b. (nih.gov)
- Severe allergic reaction (e.g., anaphylaxis) after a previous dose of any Haemophilus influenzae type b or tetanus toxoid-containing vaccine or any component of ActHIB vaccine. (nih.gov)
- ActHIB ® is a vaccine indicated for the prevention of invasive disease caused by Haemophilus influenzae (H. influenzae) type b. (nih.gov)
- In Italy, the vaccine against Haemophilus influenzae type b (Hib) was licensed in 1995, but vaccination is voluntary. (cdc.gov)
- elivaldogene autotemcel, haemophilus influenzae type b vaccine. (medscape.com)
- To characterize adverse events (AEs) after Haemophilus influenzae type b (Hib) vaccines reported to the US Vaccine Adverse Event Reporting System (VAERS), a spontaneous reporting surveillance system. (nih.gov)
- Impact of Haemophilus influenzae Type b conjugate vaccine in Mongolia: prospective population-based surveillance, 2002-2010. (bvsalud.org)
- This study assessed the impact of Haemophilus influenzae type b ( Hib ) conjugate vaccine on childhood bacterial meningitis in Ulaanbaatar, Mongolia . (bvsalud.org)
- The Haemophilus influenzae type B vaccine, also known as Hib vaccine, is a vaccine used to prevent Haemophilus influenzae type b (Hib) infection. (liu.edu)
- Participants were enrolled between September 6, 2011, and October 9, 2011 (year 1), and from October 9, 2012, through October 21, 2012 (year 2), and were randomly assigned in a 1:1 allocation to receive 1 of the 2 vaccine types. (medscape.com)
- How should I handle Haemophilus Influenzae type B (HiB) Vaccine safely? (sgh.com.sg)
- How should I dispose of Haemophilus Influenzae type B (HiB) Vaccine safely? (sgh.com.sg)
- The Hib vaccine contains extracts from the Haemophilus influenzae type b bacteria. (hse.ie)
- The vaccine works by making the body's immune system respond if the vaccinated person comes in contact with Haemophilus influenzae type b bacteria, without causing disease. (hse.ie)
- Between 95% and 100% of children become immune to Haemophilus Influenzae b (Hib) when they have completed the recommended vaccine schedule. (hse.ie)
- Haemophilus influenzae type b bacteria (Hib) were the leading cause of meningitis in children younger than 5 years old until the Hib vaccine became available. (kidshealth.org)
- The vaccine provides long-term protection from Haemophilus influenzae type b. (kidshealth.org)
Vaccines3
- H. influenzae type b was the leading cause of invasive bacterial disease among children in the United States prior to licensing of Haemophilus b conjugate vaccines in 1987. (freece.com)
- Before effective vaccines were introduced, it was estimated that one in 200 children developed invasive H influenzae type b disease by the age of 5 years. (freece.com)
- Prior to the introduction of Haemophilus influenzae type b (Hib) vaccines, Hib was the leading cause of bacterial meningitis in the United States among children younger than 4 years of age. (nationalacademies.org)
Infections5
- Haemophilus influenzae , a type of bacteria, can cause many different kinds of infections. (cdc.gov)
- Doctors consider some H. influenzae infections "invasive. (cdc.gov)
- H. influenzae can also be a common cause of ear infections in children and bronchitis in adults. (cdc.gov)
- Haemophilus influenzae type b infections in day care attendees: implications for management. (nih.gov)
- Title : Active Bacterial Core Surveillance (ABCs) Report Emerging Infections Program Network : Haemophilus influenzae, 2008 Corporate Authors(s) : National Center for Immunization and Respiratory Diseases (U.S.). Division of Bacterial Diseases. (cdc.gov)
Invasive H influenzae1
- A laboratory-based active surveillance of invasive H. influenzae disease was implemented in a sample of Italian regions in 1997 ( 4 ). (cdc.gov)
Capsular1
- Hospital microbiologists were asked to send H. influenzae isolates to the national reference laboratory at Istituto Superiore di Sanità, where all strains were assayed by polymerase chain reaction (PCR) capsular genotyping. (cdc.gov)
Vaccination2
Bacteria3
- Haemophilus influenzae type b (Hib) is bacteria that commonly causes bacterial meningitis and pneumonia and is the leading cause of other invasive diseases, such as septic arthritis (joint infection), epiglottitis (infection and swelling of the epiglottis) and cellulites (rapidly progressing skin infection which usually involves the face, head, or neck). (who.int)
- Haemophilus influenzae b (Hib) is a bacteria that can cause serious infection in humans particularly in children, but also in individuals with weakened immune system or those who have no spleen or where the spleen is damaged by disease. (hse.ie)
- Haemophilus influenzae b infection is caused by a contagious bacteria. (hse.ie)
Meningitis2
Neisseria1
- Molecular typing methods for outbreak detection and surveillance of invasive disease caused by Neisseria meningitidis, Haemophilus influenzae and Streptococcus pneumoniae, a review. (ox.ac.uk)
Infection2
- Doctors consider pneumonia an invasive infection when H. influenzae also infect the blood or fluid surrounding the lungs. (cdc.gov)
- It was not until 1933 that it was established that influenza was caused by a virus and that H. influenzae was a cause of secondary infection. (freece.com)
Disease5
- We describe the first reported cases of invasive type e Haemophilus influenzae disease in Italy. (cdc.gov)
- Active H. influenzae case finding was conducted by contacting, monthly, microbiologists from the regional laboratories of hospitals with infectious disease or pediatric wards. (cdc.gov)
- A patient with invasive disease was defined as a patient with a compatible illness, accompanied by isolation of H. influenzae from a normally sterile site or detection of Hib antigen in cerebrospinal fluid. (cdc.gov)
- We describe these five cases of invasive disease caused by H. influenzae type e (Hie). (cdc.gov)
- Transmission of invasive Haemophilus influenzae type b disease in day care settings. (nih.gov)
Diseases1
- It's entirely normal to ask yourself these types of questions, but there's something you should always remember: the more people are vaccinated, the less likely it will be for diseases to spread. (sbk.org)
Immunization1
- Three types of immunobiologics are administered for passive immunization: a) pooled human IG or IGIV, b) specific immune globulin preparations, and c) antitoxins. (cdc.gov)
Secondary1
- Secondary Haemophilus influenzae type b in day-care facilities. (nih.gov)
Antigen1
- 165 were diagnosed by isolation of H. influenzae from a normally sterile site, and 54 were diagnosed by detection of Hib antigen in cerebrospinal fluid. (cdc.gov)
Strain1
- five were due to type e strain. (cdc.gov)
Illness1
- Discuss whether an antibiotic or a different type of treatment is appropriate for your illness. (nih.gov)
Clinical1
- This need can be met with molecular and especially nucleotide sequence-based typing methods, which are fully developed in the case of N. meningitidis and which could be more widely deployed in clinical laboratories for S. pneumoniae and H. influenzae. (ox.ac.uk)
Health1
- The following is a list of health product advisories, type I recalls as well as summaries of completed safety reviews published in October 2019 by Health Canada. (canada.ca)
Molecular1
- Molecular analysis showed two distinct type e strains circulating in Italy, both containing a single copy of the capsulation locus. (cdc.gov)
Vaccine12
- On December 22, 1988, the Food and Drug Administration licensed an additional Haemophilus b Conjugate Vaccine for routine use in children greater than or equal to18 months of age. (cdc.gov)
- The manufacturer is expected to begin distribution of the Haemophilus b Conjugate Vaccine (Diphtheria CRM197 Protein Conjugate) within a few weeks. (cdc.gov)
- Recommendations of the Immunization Practices Advisory Committee for the use of Haemophilus b Conjugate Vaccine (Diphtheria Toxoid Conjugate) (1) are applicable to the new conjugate vaccine. (cdc.gov)
- In Italy, the vaccine against Haemophilus influenzae type b (Hib) was licensed in 1995, but vaccination is voluntary. (medscape.com)
- Hib vaccine can prevent Haemophilus influenzae type b (Hib) disease. (medlineplus.gov)
- Hib vaccine may be given as a stand-alone vaccine, or as part of a combination vaccine Hib vaccine may be given as a stand-alone vaccine, or as part of a combination vaccine (a type of vaccine that combines more than one vaccine together into one shot). (medlineplus.gov)
- Haemophilus influenzae type b (Hib) Vaccine Information Statement. (medlineplus.gov)
- ActHIB is a vaccine indicated for the prevention of invasive disease caused by Haemophilus influenzae type b. (nih.gov)
- Severe allergic reaction (e.g., anaphylaxis) after a previous dose of any Haemophilus influenzae type b or tetanus toxoid-containing vaccine or any component of ActHIB vaccine. (nih.gov)
- ActHIB ® is a vaccine indicated for the prevention of invasive disease caused by Haemophilus influenzae (H. influenzae) type b. (nih.gov)
- elivaldogene autotemcel, haemophilus influenzae type b vaccine. (medscape.com)
- For more information, see the Centers for Disease Control and Prevention's (CDC) Haemophilus Influenzae type b (Hib) vaccine information statement . (msdmanuals.com)
Tetanus toxoid1
- The safety and immunogenicity of Haemophilus influenzae type b (Hib) capsular polysaccharide (CPS) alone, or covalently bound to tetanus toxoid in saline solution (Hib-TT) or adsorbed onto AI(OH)3 (Hib-TT ads), were evaluated after one injection into 18- to 23-month-old healthy children in Sweden. (nih.gov)
Serotype1
- Here we define the capsule biosynthesis pathway of Haemophilus influenzae serotype b ( Hib ), a Gram-negative bacterium that causes severe infections in infants and children . (bvsalud.org)
Meningitis2
- [ 2 ] Since 1994, surveillance of H. influenzae meningitis has been conducted within the National Surveillance of Bacterial Meningitis. (medscape.com)
- Haemophilus influenzae type b (Hib) is bacteria that commonly causes bacterial meningitis and pneumonia and is the leading cause of other invasive diseases, such as septic arthritis (joint infection), epiglottitis (infection and swelling of the epiglottis) and cellulites (rapidly progressing skin infection which usually involves the face, head, or neck). (who.int)
Invasive disease3
- A patient with invasive disease was defined as a patient with a compatible illness, accompanied by isolation of H. influenzae from a normally sterile site or detection of Hib antigen in cerebrospinal fluid. (medscape.com)
- We describe these five cases of invasive disease caused by H. influenzae type e (Hie). (medscape.com)
- Healthy carriers of Haemophilus influenzae type b [Hib] play an important role in the spread of invasive disease. (who.int)
Surveillance1
- [ 3 ] A laboratory-based active surveillance of invasive H. influenzae disease was implemented in a sample of Italian regions in 1997. (medscape.com)
Bacterial1
- Haemophilus influenzae type b (Hib) is one of the leading causes of invasive bacterial infection in young children worldwide. (nih.gov)
Subject1
- Type 508 Accommodation and the title of the report in the subject line of e-mail. (cdc.gov)
Site1
- 165 were diagnosed by isolation of H. influenzae from a normally sterile site, and 54 were diagnosed by detection of Hib antigen in cerebrospinal fluid. (medscape.com)